Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06585202 · ClinicalTrials.gov registry record · Phase 2
Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic Dermatitis
A Phase 2 study, sponsored by Aclaris Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT06585202: Completed Phase 2 study, sponsored by Aclaris Therapeutics.
NCT06585202 is a Phase 2 study that has completed, run by Aclaris Therapeutics. The registered enrollment target is 14 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06585202, a Phase 2 study, has completed, sponsored by Aclaris Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
This is a Phase 2 open label study of ATI-2138 in participants with moderate to severe atopic dermatitis.
Interventions
- DRUG ATI-2138
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2024-08-19 |
| Est. Completion | 2025-03-31 |
| Phase | Phase 2 |
What the finished NCT06585202 record still lists
NCT06585202 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 1 intervention - of which ATI-2138 is the first listed.
NCT06585202 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06585202 about?
NCT06585202 is a clinical study titled "Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic Dermatitis". This is a Phase 2 open label study of ATI-2138 in participants with moderate to severe atopic dermatitis.
What is the current status of trial NCT06585202?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2024-08-19. Estimated completion is 2025-03-31.
What interventions are being tested in trial NCT06585202?
The interventions under investigation include: ATI-2138 (DRUG).
Who is sponsoring clinical trial NCT06585202?
This trial is sponsored by Aclaris Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06585202's enrollment target sits among peer trials
14 1941st of 2000 higher than 54 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy